Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
- Conditions
- Alcohol-related Liver Disease
- Interventions
- Drug: Cagrilintide placeboDrug: NNC0194-0499 placebo
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 270
- Registration Number
- NCT06409130
- Locations
- 🇧🇬
"Acibadem City Clinic UMHAT Tokuda", Sofia, Bulgaria
🇺🇸The Institute for Liver Health, Chandler, Arizona, United States
🇺🇸Arizona Liver Center, Tucson, Arizona, United States
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 150
- Registration Number
- NCT06403761
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
- Conditions
- Obesity
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 300
- Registration Number
- NCT06388187
- Locations
- 🇺🇸
Aurora FDRC Inc., Costa Mesa, California, United States
🇺🇸Clinical Trial Res Assoc,Inc, Plantation, Florida, United States
🇺🇸Midwest Inst For Clin Res, Indianapolis, Indiana, United States
A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT06370819
- Locations
- 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 34238
- Registration Number
- NCT06351748
- Locations
- 🇨🇳
Tianjin Medical University Chu Hsien-I Memorial Hospital, Tianjin, China
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
- Conditions
- Diabetes, Type 2
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 404
- Registration Number
- NCT06340854
- Locations
- 🇺🇸
Advanced Investigative Medicine, Inc., Hawthorne, California, United States
🇺🇸Scripps Whittier Diabetes Inst, La Jolla, California, United States
🇺🇸Clinical Trials Research, Lincoln, California, United States
A Research Study on Etavopivat in Participants With and Without Liver Disease
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 48
- Registration Number
- NCT06336018
- Locations
- 🇺🇸
Amer. Rrsch Corp-TX Liver Inst, San Antonio, Texas, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People
- Conditions
- Cardiometabolic DiseasesHealthy Volunteers
- Interventions
- Drug: Placebo (NNC6022-0001)
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 56
- Registration Number
- NCT06336005
- Locations
- 🇳🇱
ICON - location Groningen, Groningen, Netherlands
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 288
- Registration Number
- NCT06326047
- Locations
- 🇺🇸
Velocity Clin Res-Chula Vista, Chula Vista, California, United States
🇺🇸Valley Research, Fresno, California, United States
🇺🇸310 Clinical Research, Inglewood, California, United States
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 355
- Registration Number
- NCT06326060
- Locations
- 🇺🇸
Centennial Medical Group, Columbia, Maryland, United States
🇦🇺Momentum Clinical Research Darlinghurst, Darlinghurst, New South Wales, Australia
🇺🇸Unity Health-Searcy Medical Center, Searcy, Arkansas, United States